MedPath

Clinical evaluation of 5-ALA/SFC for cisplatin induced renal injury

Not Applicable
Conditions
nresectable gastric cancer
Registration Number
JPRN-UMIN000024642
Lead Sponsor
kawasaki medical school
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
12
Inclusion Criteria

Not provided

Exclusion Criteria

Contraindication cases of S-1 or cisplatin administration

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety of 5-ALA/SFC as the prevention of renal failure supplement
Secondary Outcome Measures
NameTimeMethod
Renal failure depression effect
© Copyright 2025. All Rights Reserved by MedPath